Skip to content
thestock.space

As of 6 Nov 2026, Deccan Health Care trades at 11.6× trailing earnings, below the industry P/E of 28.7×, and the shares are 32% below their 52-week high. Its ROCE of 3.0% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 22% and 101% a year over 3 years. The company has almost no debt. It is a small-cap company with a market cap of ₹30 Cr, ranked 138th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 30% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹12.32
Day high
₹12.32
Day low
₹11.52
Prev. close
₹11.90
Volume
4.3K

Health check

2 good · 4 to check
  • ReturnsBehind

    −30.0% over a year, better than 0 of 7 peers.

  • Price tagCheaper

    P/E 11.6 vs industry 28.7.

  • GrowthStrong

    Sales +22.1%, profit +101.0% a year over 3 years.

  • ProfitabilityWeak

    ROCE 3.0% vs peer median 17.9%.

  • Balance sheetStretched

    Practically debt-free, Piotroski 3 of 9.

  • Red flags3 to check

    Return on equity is low at 2.3%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹30 Cr, #138 of 154 in its industry by size.

Defensive

Beta 0.56 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹82 Cr · profit ₹3 Cr
Market cap
₹30 Cr
Small cap
P/E
11.6
Industry 28.7
Price to book
0.26
Peers 4.99
Dividend yield
0.00%
ROE
2.3%
Peers 14.7%
ROCE
3.0%
Peers 17.9%
Debt to equity
0.04
Debt ₹3.96 Cr
EPS (TTM)
₹1.04
OPM (TTM)
6.4%
Net margin 3.1%
Sales growth
−0.3%
Latest quarter vs a year ago
Profit growth
+22.8%
Latest quarter vs a year ago
Price to sales
0.37
EV/EBITDA 6.0

Strengths and risks

Strengths

  • Practically debt-free.
  • Quarterly profit up 22.8% on a year ago.
  • P/E of 11.6 against an industry P/E of 28.7.

Risks to check

  • Return on equity is low at 2.3%.
  • Quarterly sales down 0.3% on a year ago.
  • 32% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Deccan Health Care

Deccan Health Care Limited, a nutraceutical company provides nutritional, personal care, and food-based solutions. It produces and distributes soft gelatin capsules, food pills, vitamin supplements, and nutritional meals. The company also provides capsules, tablets, soft gels, powders, liquids, and gummies. It also exports its products. Deccan Health Care Limited was incorporated in 1996 and is based in Hyderabad, India.

Headquarters
Hyderabad
Employees
80
Sector
Healthcare
ISIN
INE452W01019
Website
deccanhealthcare.co.in

Price range

52 weeks

₹6.65₹17.85

Today

₹11.52₹12.32
Avg volume (3M)
12.7K
1-year return
minus 30.0%
From 52-week high
minus 32.3%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
DECCANDeccan Health Care12.09plus 1.60%3011.60.263.0%2.3%6.4%22.1%101.0%0.00%minus 30.0%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
22.121.417.42122.1
21.419.715.720.121.2
0.81.71.70.90.9
3.4%8.0%9.9%4.2%4.1%
00000
00.200.10.2
0.40.30.30.40.4
0.31.21.30.40.4
29.0%25.4%25.2%9.0%25.1%
0.20.910.30.3
0.100.370.410.140.12

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+22.1%
Profit CAGR 3Y
+101.0%
EPS CAGR 3Y
+61.4%
ROE
2.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
4559.775.181.9
–+32.7%+25.7%+9.1%
435671.977
23.83.24.9
4.5%6.3%4.2%6.0%
−0−0−00.9
0.10.10.10.2
1.41.51.51.5
−0.1––−0.9
0.42.21.63.3
30.4%32.6%28.9%23.8%
0.31.51.22.5
–+387.6%minus 22.4%+114.7%
0.240.800.451.01

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1720.423.424.7
64.576.58385.5
1.61.91.14
13.69.217.434.7
96.8108125149
16.815.714.415
0.9–––
00–1.8
1.42.63.61.7
77.789.7107130
96.8108125149

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−6.8−12.6−6.4−3.6
0.3−0.3−0.1−2.2
5.3147.54
−1.21.21−1.9
–−0.3−0.1−2.6
−6.8−12.9−6.6−6.2

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you